British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...

The European Commission (EC) has expanded the approval of Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18 to 59 years at increased risk of lower ...

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the ...